Abstract
This prospective, Post-Authorization Safety Surveillance (PASS) study was carried out in patients with hemophilia A or B and inhibitors treated with FEIBA for 1 year to collect real-world data on safety and effectiveness of FEIBA. The study followed a cohort design and did not make stipulations on treatment or observation schedule, as it was designed to observe routine medical practices based on physicians' treatment decisions, including whether patients received on-demand or prophylaxis with FEIBA. The attending physician maintained documentation, including medical records, laboratory reports, adverse event reports, and so on and a subject diary was used. Eighty-one patients were treated with FEIBA at 40 sites in 10 countries over a 4-year period. Sixty-nine patients (85.2%) had hemophilia A, two had (2.5%) hemophilia B, and ten (12.3%) had acquired hemophilia A. At baseline 45 patients (55.6%) were prescribed prophylaxis and 36 (44.6%) on-demand treatment. This study was novel in following safety and effectiveness in 'real world' on-demand and prophylactic use of FEIBA, and was able to collect data in these rare patients under routine clinical practice.
References
Sep 1, 1990·Transfusion·M HilgartnerJ Gill
Apr 16, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·H J EhrlichE D Gomperts
Sep 25, 2004·American Journal of Hematology·Cindy A Leissinger
May 19, 2005·Current Medical Research and Opinion·Stephen Gough
Jul 13, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·D Dimichele, C Négrier
Jul 13, 2006·Haemophilia : the Official Journal of the World Federation of Hemophilia·J AstermarkUNKNOWN EHTSB
Aug 21, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·D M DiMicheleE Santagostino
Jul 6, 2007·Haemophilia : the Official Journal of the World Federation of Hemophilia·A GringeriUNKNOWN RITS-FITNHES Study Group
Aug 29, 2007·Journal of Thrombosis and Haemostasis : JTH·B A KonkleM A Serban
Jan 28, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·A CoppolaG DI Minno
Nov 22, 2011·Blood·Charles R M HayUNKNOWN International Immune Tolerance Study
Feb 11, 2012·Journal of Thrombosis and Haemostasis : JTH·P KnoeblUNKNOWN EACH2 Registry Contributors
May 24, 2012·Blood·Francesco BaudoUNKNOWN EACH2 registry contributors
May 29, 2012·Journal of Thrombosis and Haemostasis : JTH·M Hoffman, Y Dargaud
Jun 5, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·A GringeriL G Mantovani
Aug 6, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·S V AntunesW-Y Wong
Sep 10, 2013·Seminars in Thrombosis and Hemostasis·Massimo FranchiniGiuseppe Lippi
Apr 26, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·A C GoodeveJ Oldenburg
Nov 2, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·J-Y BorgUNKNOWN FEIBHAC Study Group
Citations
Apr 20, 2017·Journal of Clinical Medicine·Angiola RocinoAntonio Coppola
Feb 24, 2018·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Anita ÁrokszállásiÁgota Schlammadinger
Oct 9, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·Johnny MahlanguRebecca Kruse-Jarres
Sep 29, 2018·Journal of Thrombosis and Haemostasis : JTH·A D ShapiroS Nasr
Jan 4, 2018·Blood Advances·Matteo RotaLorenzo G Mantovani
Aug 14, 2020·Curēus·Hafiz M AslamRehan Shah
Jul 28, 2020·Hämostaseologie·Hans H BrackmannClaude Négrier
Nov 16, 2021·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Daniela NemeMauro Davoli